Read on Twitter
New publication alert 
Just published in @alzdemjournals
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
https://doi.org/10.1002/alz.12236
A thread (1/n)
Just published in @alzdemjournals
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
https://doi.org/10.1002/alz.12236
A thread (1/n)
Motivation: Several studies have shown outstanding diagnostic potentials of p-tau biomarkers in cerebrospinal fluid and blood.
However, there is an ongoing debate as to if p-tau217 is better than p-tau181 as a biomarker for #Alzheimers
However, there is an ongoing debate as to if p-tau217 is better than p-tau181 as a biomarker for #Alzheimers
3/ Approach: we went back to cerebrospinal fluid where Alzheimer brain biochemical changes first reflect before blood. We performed a head-to-head comparison in unselected memory clinic cohorts, including MCI who were only amyloid positive (A+T-N-).
4/ Our working hypothesis is that p-tau biomarkers measured on N-terminal tau entities become abnormal ahead of the standard assays currently being used in the clinics (which target the mid-region of tau).
